These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31919775)

  • 21. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease.
    Ayabe R; Rootman DB; Hwang CJ; Ben-Artzi A; Goldberg R
    Ophthalmic Plast Reconstr Surg; 2014; 30(5):415-9. PubMed ID: 24978425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thyroid eye disease: therapy in the active phase.
    Bhatti MT; Dutton JJ
    J Neuroophthalmol; 2014 Jun; 34(2):186-97. PubMed ID: 24821102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical treatment in thyroid eye disease in 2020.
    Khong JJ; McNab A
    Br J Ophthalmol; 2021 Mar; 105(3):299-305. PubMed ID: 32447327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic indicators for the development of strabismus among patients with graves' ophthalmopathy.
    Lin TY; Li N; Yeh MW; Leung AM; Rootman DB
    J Clin Transl Endocrinol; 2017 Sep; 9():38-40. PubMed ID: 29067268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy.
    Edmunds MR; Boelaert K
    Thyroid; 2019 Apr; 29(4):557-562. PubMed ID: 30688164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiotherapy for Active Thyroid Eye Disease.
    Godfrey KJ; Kazim M
    Ophthalmic Plast Reconstr Surg; 2018; 34(4S Suppl 1):S98-S104. PubMed ID: 29771752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease.
    Shams PN; Ma R; Pickles T; Rootman J; Dolman PJ
    Am J Ophthalmol; 2014 Jun; 157(6):1299-305. PubMed ID: 24582992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fingolimod Improves the Outcome of Experimental Graves' Disease and Associated Orbitopathy by Modulating the Autoimmune Response to the Thyroid-Stimulating Hormone Receptor.
    Plöhn S; Hose M; Schlüter A; Michel L; Diaz-Cano S; Hendgen-Cotta UB; Banga JP; Bechrakis NE; Hansen W; Eckstein A; Berchner-Pfannschmidt U
    Thyroid; 2019 Sep; 29(9):1286-1301. PubMed ID: 31237525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of thyroid eye disease in the United Kingdom: A multi-centre thyroid eye disease audit.
    Mellington FE; Dayan CM; Dickinson AJ; Hickey JL; MacEwen CJ; McLaren J; Perros P; Rose GE; Uddin J; Vaidya B; Foley P; Lazarus JH; Mitchell A; Ezra DG;
    Orbit; 2017 Jun; 36(3):159-169. PubMed ID: 28296512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study.
    Ng CM; Yuen HK; Choi KL; Chan MK; Yuen KT; Ng YW; Tiu SC
    Hong Kong Med J; 2005 Oct; 11(5):322-30. PubMed ID: 16219950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TSHR Signaling Stimulates Proliferation Through PI3K/Akt and Induction of miR-146a and miR-155 in Thyroid Eye Disease Orbital Fibroblasts.
    Woeller CF; Roztocil E; Hammond C; Feldon SE
    Invest Ophthalmol Vis Sci; 2019 Oct; 60(13):4336-4345. PubMed ID: 31622470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves' ophthalmopathy patients.
    van Steensel L; Hooijkaas H; Paridaens D; van den Bosch WA; Kuijpers RW; Drexhage HA; van Hagen PM; Dik WA
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E944-53. PubMed ID: 22438231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.
    van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
    Thyroid; 2010 May; 20(5):535-44. PubMed ID: 20384487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug safety in thyroid eye disease - a systematic review.
    Wolf J; Mitka KI; Hubalewska-Dydejczyk A; Krämer I; Kahaly GJ
    Expert Opin Drug Saf; 2022 Jul; 21(7):881-912. PubMed ID: 35447047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological treatments for thyroid eye disease.
    Modjtahedi SP; Modjtahedi BS; Mansury AM; Selva D; Douglas RS; Goldberg RA; Leibovitch I
    Drugs; 2006; 66(13):1685-700. PubMed ID: 16978034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Superior ophthalmic vein thrombosis: A rare complication of Graves' orbitopathy.
    Sorrentino D; Taubenslag KJ; Bodily LM; Duncan K; Stefko T; Yu JY
    Orbit; 2018 Jun; 37(3):175-178. PubMed ID: 29053044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach.
    Sipkova Z; Insull EA; David J; Turner HE; Keren S; Norris JH
    Clin Endocrinol (Oxf); 2018 Dec; 89(6):834-839. PubMed ID: 30103255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A New Era in the Treatment of Thyroid Eye Disease.
    Patel A; Yang H; Douglas RS
    Am J Ophthalmol; 2019 Dec; 208():281-288. PubMed ID: 31377284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Socioeconomic Disparities in the Presentation and Treatment of Graves' Disease and Thyroid Eye Disease.
    Vargason CW; Chelnis JG; Barahimi BI; Mawn LA
    Semin Ophthalmol; 2016; 31(4):409-14. PubMed ID: 27385363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy.
    Yin X; Latif R; Bahn R; Tomer Y; Davies TF
    Thyroid; 2008 Nov; 18(11):1201-6. PubMed ID: 18925838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.